Beyond the Pillの世界市場

Beyond the Pillの世界市場は2030年までに3億8,190万米ドルに達する見込み

2024年に2億8,720万米ドルと推定されるBeyond the Pillの世界市場は、2024年から2030年にかけてCAGR 4.9%で成長し、2030年には3億8,190万米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるサービス提供サービスは、CAGR 3.8%を記録し、分析期間終了時には1億3,830万米ドルに達すると予測されます。モニタリング提供セグメントの成長率は、分析期間中CAGR 5.8%と推定されます。

米国市場は7,820万米ドルと推定、中国はCAGR 7.5％で成長予測

米国のBeyond the Pill市場は、2024年に7,820万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに7,460万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.4％と4.8％と予測されています。欧州では、ドイツがCAGR 3.1%で成長すると予測されています。

世界の「Beyond the Pill」市場- 主要動向と促進要因のまとめ

なぜ「Beyond the Pill」コンセプトが現代のヘルスケア提供に革命をもたらすのか？

Beyond the Pill"コンセプトは、ヘルスケアを、薬の販売のみに焦点を当てた取引モデルから、患者のあらゆるニーズに対応する総合的なアウトカムベースのアプローチへと変革しつつあります。このモデルには、アドヒアランス、患者教育、遠隔モニタリング、診断、個別化介入をサポートするサービスやテクノロジーが含まれます。慢性疾患の負担が増加し、世界中のヘルスケアシステムが持続不可能なコストと闘う中、"Beyond the Pill"イニシアチブは患者の転帰を改善し、費用対効果の高いケアを推進する上で不可欠なツールとなりつつあります。ヘルスケアプロバイダーや製薬会社は、錠剤を終点とみなすのではなく、より広範で統合されたケア経路の出発点として扱うようになっています。例えば、モバイルヘルスアプリ、遠隔診察プラットフォーム、ウェアラブルデバイスなどのデジタルツールを提供し、患者のバイタルや服薬コンプライアンスをリアルタイムで追跡できるようにしています。これらのサービスは、早期介入を可能にし、病院の再入院を減らし、患者とケアチームの長期的な関与を促進します。焦点は薬の販売から結果の提供へとシフトしており、患者はよりパーソナライズされた双方向のケアモデルに肯定的な反応を示しています。規制機関や支払者も、現実のアウトカムを改善する「Beyond the Pill」プログラムの可能性を認識し、その採用にインセンティブを与えています。このパラダイムシフトは、世界中でよりレジリエントでプロアクティブな、患者中心のヘルスケアシステムの基礎を築きつつあります。

デジタルヘルスツールとAIは、「Beyond the Pill」エコシステムをどのように強化しているのか？

テクノロジーは"Beyond the Pill"革命の中核であり、前例のないパーソナライゼーション、拡張性、患者ケアにおけるリアルタイムのフィードバックを可能にします。モバイルアプリ、ウェアラブル、スマートピルボトル、遠隔モニタリング機器などのデジタルヘルスツールは、現在では医薬品治療とシームレスに統合され、診断、治療、継続的ケアのギャップを埋めるコネクテッド・エコシステムを作り出しています。人工知能（AI）と機械学習は、これらのツールによって生成される大規模なデータセットの分析において極めて重要な役割を果たし、リスクのある患者の特定、アドヒアランス動向の監視、治療計画の微調整に役立つ予測的洞察を提供します。例えば、AI対応のチャットボットやバーチャルヘルスアシスタントは、患者に服薬スケジュールを案内したり、行動を促したり、さらには症状が悪化した場合に臨床医に警告を発したりすることができます。クラウドベースのプラットフォームは、患者、医療提供者、支払者の間で一元的なデータ共有を可能にし、ケアの透明性と継続性を高める。製薬会社は、治療価値を拡大し、患者のロイヤルティを向上させるオーダーメイドのソリューションを共同開発するために、ヘルステック企業とパートナーシップを結ぶことが増えています。こうした提携により、コンパニオン診断、バーチャルコーチング、症状トラッカー、さらにはAIを活用したメンタルヘルスサポートまで、すべて本来の処方箋に沿った形で提供することが可能になります。さらに、ブロックチェーン技術は、コンプライアンスと信頼に不可欠なエコシステム内のデータセキュリティとトレーサビリティを確保する役割を果たし始めています。これらの技術的進歩が相まって、製薬業界のバリューチェーンが再構築され、データ主導型のケアコーディネーションが治療介入の中心に据えられつつあります。

Beyond the Pill」モデルの採用を加速させている利害関係者とヘルスケア動向とは？

Beyond the Pill"戦略の採用は、患者、医療提供者、支払者、政策立案者の期待の進化によって急速に加速しています。デジタルツールとヘルスリテラシーの向上により力を得た患者は、効果的なだけでなく、個別化され、利便性が高く、継続的なケアを求めるようになっています。彼らは、栄養アドバイス、メンタルヘルスのサポート、ライフスタイルのコーチングなど、薬物療法にとどまらないサービスによってヘルスケアの旅がサポートされることを期待しており、ホリスティックケアは贅沢品ではなく必需品となっています。ヘルスケアプロバイダー、特にバリュー・ベース・ケアやACO（アカウンタブル・ケア・オーガニゼーション）の下で働くプロバイダーは、病気の進行を予防し、費用のかかる再入院を回避するインセンティブを与えられており、コンパニオンサービスや遠隔モニタリングへの関心が高まっています。増大する慢性期医療費の抑制を目指す支払者や保険会社は、服薬アドヒアランスや予防的健康管理を促進する統合モデルを支持しています。製薬会社自身も、特許の崖、規制当局の監視、価格の透明性を求める社会的要求など、高まる圧力に直面しています。競争力と関連性を維持するために、製薬会社は単なる製品ではなく、測定可能な成果を提供するサービス志向の組織へと進化しています。人口の高齢化、非伝染性疾患の増加、パンデミック後の回復といった世界の健康課題は、継続的な患者参加と医療システムの回復力の重要性をさらに際立たせています。これらのシフトが相まって、断片的で反応的なケアから、協調的で積極的な健康管理への移行が促進され、"Beyond the Pill"は21世紀のヘルスケア提供に不可欠なフレームワークとして位置づけられています。

世界の「Beyond the Pill」市場の成長を促進しているものは何か？

世界の"Beyond the Pill"市場の成長は、技術の進歩、進化するヘルスケア経済、規制上のインセンティブ、患者中心のビジネス戦略など、いくつかの集約的な力によって推進されています。糖尿病、心血管疾患、がんなどの慢性疾患の蔓延が拡大しているため、単純な薬物投与にとどまらない長期的なケアモデルが必要とされています。この需要は、デジタル治療薬、コネクテッドデバイス、遠隔医療サービス、医薬品治療と連動する患者支援プログラムへの投資に拍車をかけています。政府や保険プロバイダーが価値ベースの償還モデルにシフトするにつれ、実臨床でのアウトカム、アドヒアランス、総費用がますます重視されるようになっています。製薬業界は、製品発売にサービスを組み込み、デジタルプラットフォームを構築し、教育、モニタリング、フィードバックループを含むエンドツーエンドの患者エコシステムを構築することで対応しています。さらに、新興市場でもスマートフォンとインターネットアクセスが広く普及したことで、以前はアクセスできなかったスケーラブルでデータリッチなソリューションが可能になりつつあります。製薬企業とデジタルヘルス新興企業との戦略的提携は、イノベーションを加速し、新サービスの市場投入までの時間を短縮しています。EU、米国、アジア太平洋などの地域の規制機関は、デジタルヘルス認証と償還の枠組みを提供し、こうした統合ケアアプローチをますます支持しています。さらに、デジタルヘルスやヘルステック・サービスに対する投資家の関心は過去最高水準にあり、研究開発や事業拡大に必要な資金が市場に流入しています。これらの要因が相まって、活気に満ちた高成長の「Beyond the Pill」エコシステムが構築されつつあり、製薬業界の役割は単なる医薬品の供給者としてではなく、長期的な健康アウトカムにおける包括的なパートナーとして再定義されつつあります。

セグメント

提供（サービス提供、モニタリング提供、支援提供、情報提供、教育提供）;治療分野（糖尿病、がん、心血管疾患、喘息、その他の治療分野）

調査対象企業の例

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• Bio-Images Drug Delivery Ltd
• CapsoVision Inc.
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly and Company
• etectRx Inc.
• F. Hoffmann-La Roche AG
• GlaxoSmithKline plc（GSK）
• Johnson & Johnson
• Mankind Pharma Ltd.
• Medtronic plc
• Merck & Co., Inc.
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.

AI統合

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革します。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Beyond the Pill Market to Reach US$381.9 Million by 2030

The global market for Beyond the Pill estimated at US$287.2 Million in the year 2024, is expected to reach US$381.9 Million by 2030, growing at a CAGR of 4.9% over the analysis period 2024-2030. Services Offering, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$138.3 Million by the end of the analysis period. Growth in the Monitoring Offering segment is estimated at 5.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$78.2 Million While China is Forecast to Grow at 7.5% CAGR

The Beyond the Pill market in the U.S. is estimated at US$78.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$74.6 Million by the year 2030 trailing a CAGR of 7.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 4.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Global “Beyond the Pill” Market - Key Trends & Drivers Summarized

Why Is the “Beyond the Pill” Concept Revolutionizing Modern Healthcare Delivery?

The “Beyond the Pill” concept is transforming healthcare from a transactional model focused solely on medication sales to a holistic, outcomes-based approach that addresses the full spectrum of patient needs. Originating from the pharmaceutical industry’s effort to add value to drug therapies, this model includes services and technologies that support adherence, patient education, remote monitoring, diagnostics, and personalized interventions. As chronic disease burdens rise and healthcare systems worldwide grapple with unsustainable costs, “Beyond the Pill” initiatives are becoming vital tools in improving patient outcomes and driving cost-effective care. Rather than viewing the pill as the endpoint, healthcare providers and pharmaceutical companies now treat it as the starting point for broader, integrated care pathways. For example, companies offer digital tools-such as mobile health apps, teleconsultation platforms, and wearable devices-that help track patient vitals and medication compliance in real time. These services enable earlier intervention, reduce hospital readmissions, and foster long-term engagement between patients and care teams. The focus is shifting from selling pills to delivering results, and patients are responding positively to more personalized, interactive care models. Regulatory agencies and payers are also recognizing the potential of “Beyond the Pill” programs in improving real-world outcomes and are incentivizing their adoption. This paradigm shift is laying the foundation for more resilient, proactive, and patient-centric healthcare systems across the globe.

How Are Digital Health Tools and AI Empowering the “Beyond the Pill” Ecosystem?

Technology is at the heart of the “Beyond the Pill” revolution, enabling unprecedented personalization, scalability, and real-time feedback in patient care. Digital health tools such as mobile apps, wearables, smart pill bottles, and remote monitoring devices are now seamlessly integrated with pharmaceutical treatments, creating a connected ecosystem that bridges the gap between diagnosis, treatment, and ongoing care. Artificial intelligence (AI) and machine learning play a pivotal role in analyzing large datasets generated by these tools, providing predictive insights that help identify at-risk patients, monitor adherence trends, and fine-tune treatment plans. For instance, AI-enabled chatbots and virtual health assistants can guide patients through medication schedules, provide behavioral nudges, and even alert clinicians in case of deteriorating symptoms. Cloud-based platforms allow for centralized data sharing between patients, providers, and payers, enhancing transparency and continuity of care. Pharmaceutical companies are increasingly entering partnerships with health tech firms to co-develop tailored solutions that extend therapeutic value and improve patient loyalty. These collaborations enable the delivery of companion diagnostics, virtual coaching, symptom trackers, and even AI-driven mental health support-all aligned with the original prescription. Additionally, blockchain technology is beginning to play a role in ensuring data security and traceability within the ecosystem, which is vital for compliance and trust. Together, these technological advancements are reshaping the value chain of the pharmaceutical industry and placing data-driven care coordination at the center of therapeutic interventions.

What Stakeholders and Healthcare Trends Are Accelerating Adoption of “Beyond the Pill” Models?

The adoption of “Beyond the Pill” strategies is being rapidly accelerated by the evolving expectations of patients, healthcare providers, payers, and policymakers who are all seeking more value from pharmaceutical interventions. Patients, empowered by digital tools and better health literacy, now demand care that is not only effective but also personalized, convenient, and continuous. They expect their healthcare journeys to be supported by services that go beyond medication-such as nutritional advice, mental health support, and lifestyle coaching-making holistic care a necessity rather than a luxury. Healthcare providers, particularly those working under value-based care or accountable care organizations (ACOs), are incentivized to prevent disease progression and avoid costly readmissions, leading to increased interest in companion services and remote monitoring. Payers and insurers, looking to control escalating chronic care costs, are backing integrated models that promote medication adherence and preventive health management. Pharmaceutical companies themselves face mounting pressure from patent cliffs, regulatory scrutiny, and public demand for price transparency. To stay competitive and relevant, they are evolving into service-oriented organizations that deliver measurable outcomes rather than just products. Global health challenges-such as aging populations, rising non-communicable diseases, and post-pandemic recovery-further underscore the importance of ongoing patient engagement and health system resilience. Collectively, these shifts are catalyzing a move from fragmented, reactionary care to coordinated, proactive health management, positioning “Beyond the Pill” as a critical framework for 21st-century healthcare delivery.

What Is Fueling the Growth in the Global “Beyond the Pill” Market?

The growth in the global “Beyond the Pill” market is driven by several converging forces, including technological advancement, evolving healthcare economics, regulatory incentives, and patient-centric business strategies. The growing prevalence of chronic diseases such as diabetes, cardiovascular disorders, and cancer necessitates long-term care models that extend far beyond simple drug administration. This demand is fueling investment in digital therapeutics, connected devices, telemedicine services, and patient support programs that work in tandem with pharmaceutical treatments. As governments and insurance providers shift toward value-based reimbursement models, there is increasing emphasis on real-world outcomes, adherence, and total cost of care-objectives that “Beyond the Pill” programs are uniquely positioned to address. The pharmaceutical industry is responding by embedding services into product launches, building digital platforms, and creating end-to-end patient ecosystems that include education, monitoring, and feedback loops. Additionally, the widespread penetration of smartphones and internet access, even in emerging markets, is enabling scalable, data-rich solutions that were previously inaccessible. Strategic alliances between pharma companies and digital health startups are accelerating innovation and shortening time-to-market for new service offerings. Regulatory bodies in regions such as the EU, U.S., and Asia-Pacific are increasingly supportive of these integrated care approaches, providing frameworks for digital health certification and reimbursement. Furthermore, investor interest in digital health and health-tech services is at an all-time high, infusing the market with capital needed for R&D and expansion. Together, these drivers are creating a vibrant and high-growth “Beyond the Pill” ecosystem that is redefining the pharmaceutical industry’s role-not just as a supplier of drugs, but as a comprehensive partner in long-term health outcomes.

SCOPE OF STUDY:

The report analyzes the Beyond the Pill market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Offering (Services Offering, Monitoring Offering, Assistance Offering, Information Offering, Education Offering); Therapeutic Area (Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area, Asthma Therapeutic Area, Other Therapeutic Areas)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• Bio-Images Drug Delivery Ltd
• CapsoVision Inc.
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly and Company
• etectRx Inc.
• F. Hoffmann-La Roche AG
• GlaxoSmithKline plc (GSK)
• Johnson & Johnson
• Mankind Pharma Ltd.
• Medtronic plc
• Merck & Co., Inc.
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Beyond the Pill - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Value-Based Care Models Throw the Spotlight on Beyond-the-Pill Strategies to Improve Outcomes
  • Shift Toward Patient-Centric Healthcare Spurs Growth in Digital Therapeutics and Support Programs
  • Pharma's Need to Differentiate in Crowded Markets Strengthens the Business Case for Non-Drug Services
  • Here's How Real-World Evidence Is Driving Adoption of Digital Health Platforms Accompanying Therapies
  • Integration of Companion Apps, Adherence Tools, and Coaching Expands the Addressable Value Proposition
  • Chronic Disease Management Trends Generate Long-Term Opportunities for Behavioral and Educational Interventions
  • Data-Driven Patient Engagement Platforms Accelerate Evolution of the Traditional Drug Lifecycle
  • Rise of Personalized Medicine Drives Development of Customized Digital and Service-Based Add-Ons
  • Telehealth Normalization Reinforces Role of Remote Monitoring and Patient Support Tools
  • Growing Employer Focus on Outcomes-Based Wellness Programs Creates B2B Opportunities for Beyond-the-Pill Offerings
  • Wearables and Connected Devices Propel Integration of Continuous Monitoring into Drug Therapies
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Beyond the Pill Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Beyond the Pill by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Beyond the Pill by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Beyond the Pill by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Services Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Services Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Services Offering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Monitoring Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Monitoring Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Monitoring Offering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Assistance Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Assistance Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Assistance Offering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Information Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Information Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Information Offering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Education Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Education Offering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Education Offering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Diabetes Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Diabetes Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Diabetes Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Oncology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Oncology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Oncology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Cardiovascular Diseases Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Cardiovascular Diseases Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Cardiovascular Diseases Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Asthma Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Asthma Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Asthma Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Beyond the Pill Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 43: Canada 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 46: Canada 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• JAPAN
  • Beyond the Pill Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 49: Japan 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 52: Japan 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• CHINA
  • Beyond the Pill Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 53: China Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: China Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 55: China 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 56: China Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 58: China 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• EUROPE
  • Beyond the Pill Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Beyond the Pill by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Beyond the Pill by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 61: Europe 16-Year Perspective for Beyond the Pill by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 64: Europe 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 67: Europe 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• FRANCE
  • Beyond the Pill Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 68: France Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: France Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 70: France 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 71: France Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: France Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 73: France 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• GERMANY
  • Beyond the Pill Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 74: Germany Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Germany Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 76: Germany 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 77: Germany Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Germany Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 79: Germany 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 80: Italy Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Italy Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 82: Italy 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 83: Italy Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Italy Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 85: Italy 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Beyond the Pill Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 86: UK Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: UK Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 88: UK 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 89: UK Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: UK Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 91: UK 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 92: Spain Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Spain Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 94: Spain 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 95: Spain Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Spain Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 97: Spain 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 98: Russia Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Russia Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 100: Russia 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 101: Russia Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Russia Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 103: Russia 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Rest of Europe Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 106: Rest of Europe 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Rest of Europe Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 109: Rest of Europe 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Beyond the Pill Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Beyond the Pill by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 111: Asia-Pacific Historic Review for Beyond the Pill by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 112: Asia-Pacific 16-Year Perspective for Beyond the Pill by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Asia-Pacific Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 115: Asia-Pacific 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Asia-Pacific Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 118: Asia-Pacific 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Beyond the Pill Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 119: Australia Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Australia Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 121: Australia 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 122: Australia Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Australia Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 124: Australia 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• INDIA
  • Beyond the Pill Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 125: India Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: India Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 127: India 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 128: India Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: India Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 130: India 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 131: South Korea Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: South Korea Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 133: South Korea 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 134: South Korea Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: South Korea Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 136: South Korea 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Asia-Pacific Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Asia-Pacific Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 142: Rest of Asia-Pacific 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Beyond the Pill Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 143: Latin America Recent Past, Current & Future Analysis for Beyond the Pill by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 144: Latin America Historic Review for Beyond the Pill by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 145: Latin America 16-Year Perspective for Beyond the Pill by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 146: Latin America Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Latin America Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 148: Latin America 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 149: Latin America Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Latin America Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 151: Latin America 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 152: Argentina Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Argentina Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 154: Argentina 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 155: Argentina Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Argentina Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 157: Argentina 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 158: Brazil Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Brazil Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 160: Brazil 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 161: Brazil Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Brazil Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 163: Brazil 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 164: Mexico Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Mexico Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 166: Mexico 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 167: Mexico Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Mexico Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 169: Mexico 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Rest of Latin America Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 172: Rest of Latin America 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Rest of Latin America Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 175: Rest of Latin America 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Beyond the Pill Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 176: Middle East Recent Past, Current & Future Analysis for Beyond the Pill by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 177: Middle East Historic Review for Beyond the Pill by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 178: Middle East 16-Year Perspective for Beyond the Pill by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 179: Middle East Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Middle East Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 181: Middle East 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 182: Middle East Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Middle East Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 184: Middle East 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 185: Iran Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Iran Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 187: Iran 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 188: Iran Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Iran Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 190: Iran 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 191: Israel Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Israel Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 193: Israel 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 194: Israel Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Israel Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 196: Israel 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Saudi Arabia Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 199: Saudi Arabia 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Saudi Arabia Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 202: Saudi Arabia 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 203: UAE Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: UAE Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 205: UAE 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 206: UAE Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: UAE Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 208: UAE 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Rest of Middle East Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 211: Rest of Middle East 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Rest of Middle East Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 214: Rest of Middle East 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030
• AFRICA
  • Beyond the Pill Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 215: Africa Recent Past, Current & Future Analysis for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Africa Historic Review for Beyond the Pill by Offering - Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 217: Africa 16-Year Perspective for Beyond the Pill by Offering - Percentage Breakdown of Value Sales for Services Offering, Monitoring Offering, Assistance Offering, Information Offering and Education Offering for the Years 2014, 2025 & 2030
  • TABLE 218: Africa Recent Past, Current & Future Analysis for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Africa Historic Review for Beyond the Pill by Therapeutic Area - Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 220: Africa 16-Year Perspective for Beyond the Pill by Therapeutic Area - Percentage Breakdown of Value Sales for Other Therapeutic Areas, Diabetes Therapeutic Area, Oncology Therapeutic Area, Cardiovascular Diseases Therapeutic Area and Asthma Therapeutic Area for the Years 2014, 2025 & 2030

IV. COMPETITION